Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00025584 · ClinicalTrials.gov registry record · Phase 2
PS-341 in Treating Women With Metastatic Breast Cancer
A Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT00025584: Completed Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, sponsored by National Cancer Institute (NCI).
NCT00025584 is a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 35 participants, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (46% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00025584, a Phase 2 study of Stage IV Breast Cancer and Recurrent Breast Cancer, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer
Primary Outcome
The agent would be of definite interest for further investigation if the associated response rate is at least 30% (p1), and would not be of further interest if the response rate is below 10% (p0).
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG bortezomib
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2001-08 |
| Phase | Phase 2 |
What the finished NCT00025584 record still lists
NCT00025584 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 35 participants, a relatively small participant target, below the 65-participant average among 30 other Stage IV Breast Cancer trials with a reported enrollment target (46% lower).
The record links to 2 conditions, with Stage IV Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00025584 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00025584 about?
NCT00025584 is a clinical study titled "PS-341 in Treating Women With Metastatic Breast Cancer". PS-341 may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth. Phase II trial to study the effectiveness of PS-341 in treating women who have metastatic breast cancer
What is the current status of trial NCT00025584?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 35 participants. The study started on 2001-08.
What conditions does trial NCT00025584 study?
This clinical trial studies the following conditions: Stage IV Breast Cancer, Recurrent Breast Cancer.
What interventions are being tested in trial NCT00025584?
The interventions under investigation include: laboratory biomarker analysis (OTHER), bortezomib (DRUG).
Who is sponsoring clinical trial NCT00025584?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00025584 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stage IV Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00025584's enrollment target sits among peer trials
35 11th of 30 higher than 19 of 30 other Stage IV Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Stage IV Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
RECRUITING · Phase 2
-
Avelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer
RECRUITING · Phase 2
-
Pertuzumab, Trastuzumab, and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With HER2-Positive Advanced Breast Cancer
ACTIVE NOT RECRUITING · Phase 2
-
MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer
COMPLETED · Phase 2
-
Trastuzumab and Interleukin-2 in Treating Patients With Metastatic Breast Cancer
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01697371 · 35 participants · NA
Proton Therapy in the Treatment of Liver Metastases
- NCT01940757 · 35 participants · Phase 1
Experimental Infection of Hookworm-naïve Adults With Dermally-applied Infectious Necator Americanus Hookworm Larvae
- NCT02235857 · 35 participants · NA
Post Approval Study of Liposorber LA-15 System for the Treatment of Focal Segmental Glomerulosclerosis in Children
- NCT02637934 · 35 participants · Phase 1
Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia